transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model

Författare och institution:
Anneli Schmitt (Institutionen för särskilda specialiteter, Avdelningen för radiofysik); Peter Bernhardt (Institutionen för särskilda specialiteter, Avdelningen för radiofysik); Ola Nilsson (Institutionen för laboratoriemedicin , Avdelningen för patologi); Håkan Ahlman (Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi); Lars Kölby (Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi); Eva Forssell-Aronsson (Institutionen för särskilda specialiteter, Avdelningen för radiofysik)
Publicerad i:
Cancer biotherapy & radiopharmaceuticals, 20 ( 2 ) s. 231-6
1084-9785 (Print)
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
AIM: (177)Lu-DOTA-Tyr(3)-octreotate is a candidate radiopharmaceutical for the therapy of somatostatin receptor (sstr)-positive small cell lung cancer (SCLC). Scintigraphy of lung tumors is made with 2 alternative somatostatin analogs, (111)In-DTPA-octreotide or (99m)Tc-depreotide. The aim of this study was to compare the biodistribution of these 3 radiopharmaceuticals in SCLC xenografted to nude mice. METHODS: Nude mice, bearing tumors from the human SCLC cell line NCI-H69, were intravenously injected with 10 MBq (2.4 microg) (99m)Tc-depreotide and 2 MBq (0.5 microg) (111)In-DTPA-octreotide simultaneously. The activity concentration (%IA/g) was measured in tumor and normal tissue at 2, 4, and 24 hours postinjection (hpi). The results were compared with earlier published biodistribution data of 3 MBq (0.7 microg) (177)Lu-DOTA-Tyr(3)-octreotate in the same animal model. RESULTS: The activity concentration of (111)In-DTPAoctreotide in tumor was higher than the activity concentration of (99m)Tc-depreotide at 2-24 hpi, p < 0.05. The highest tumor uptake at 24 hpi was, however, found for (177)Lu-DOTA-Tyr(3)-octreotate. The activity concentration of (99m)Tc-depreotide was significantly higher in the heart, lungs, liver, the salivary glands, spleen, and bone marrow than for (111)In-DTPA-octreotide at 2-24 hpi. Saturation of the somatostatin receptors may have influenced the uptake in tumor and sstr-positive normal tissues. CONCLUSION: The low tumor-to-lung and tumor-to-liver activity concentration ratios for (99m)Tc-depreotide could result in a lower detection rate of SCLC with this compound versus (111)In-DTPA-octreotide. (177)Lu-DOTA-Tyr(3)-octreotate gave the highest tumor-activity concentration, and has, thus, the best properties for therapy.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Animals, Carcinoma, Small Cell/*radiotherapy, Cell Line, Tumor, Disease Models, Animal, Humans, Indium Radioisotopes/pharmacokinetics, Liver/pathology, Lung/pathology, Lung Neoplasms/*radiotherapy, Mice, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental/therapy, Octreotide/*analogs & derivatives/*pharmacokinetics, Organometallic Compounds/*pharmacokinetics, Organotechnetium Compounds/*pharmacokinetics, Pentetic Acid/*analogs & derivatives/*pharmacokinetics, Radiopharmaceuticals, Somatostatin/*analogs & derivatives/*pharmacokinetics, Time Factors, Tissue Distribution
Postens nummer:
Posten skapad:
2007-09-04 13:09
Posten ändrad:
2010-01-26 12:48

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007